摘要
目的:探讨左卡尼汀辅助治疗慢性心力衰竭的疗效及其安全性。方法:选取我科慢性心力衰竭住院患者60例,随机分为左卡尼汀治疗组和对照组。两组均接受利尿剂、洋地黄等常规抗心衰治疗,左卡尼汀治疗组在常规治疗基础上加用左卡尼汀3g/次,每天一次,连续静脉注射7 d。治疗前后测定和比较两组患者的血清半乳糖凝集素3和脑钠尿肽(BNP)水平、6 min最大步行距离(6MWT)、左室射血分数(LVEF)及心功能。结果:治疗前,两组Galectin-3、BNP水平、LVEF、6 min最大步行距离比较均无统计学差异(P>0.05)。治疗后,两组Galectin-3、BNP水平均分别显著低于治疗前,而LVEF、6 min最大步行距离均分别显著高于治疗前,差异均有统计学意义(P<0.05),且左卡尼汀治疗组Galectin-3、BNP水平显著低于对照组,而LVEF、6 min最大步行距离显著高于对照组,差异均有统计学意义(P<0.05)。治疗后,左卡尼汀治疗组和对照组的治疗总有效率分别为96.7%和80%,左卡尼汀治疗组显著高于对照组(P<0.05)。两组不良反应的发生情况比较无明显统计学差异(P>0.05)。结论:常规治疗的基础上联合左卡尼汀可以显著改善心衰患者的心功能,增加其运动耐量,改善患者的预后,且无明显不良反应,值得在临床上推广应用。
Objective： To explore the efficacy and security of L-carnitine on the cardiac function of patients with chronic heart failure.Methods： 60 hospitalized patients of chronic heart failure in our department were selected and randomly divided into the treatment group and control group.Both groups received the conventional treatment including diuretics,and digitalis,etc.The treatment group was assigned to the dosage of L-carnitine 3 g per day intravenously for the seven days on the basis of the conventional therapy.The Galectin-3 and brain natriuretic peptide（BNP） concentration,6 min maximum walking distance,left ventricular ejection fraction（LVEF） and heart function before and after treatment were measured and compared in both two groups.Results： Before treatment,no signnificant difference was found in the serum Galectin-3 and BNP levels,LVEF,6 min maximum walking distance between two groups（P0.05）.After treatment,the serum Galectin-3 and BNP levels of both groups were significantly lower than those before treatment,respectively;while LVEF and 6 min maximum walking distance were respectively higher than those before treatment（P0.05）.Moreover,the serum levels of Galectin-3,BNP were significantly lower in the L-carnitine group than those of the control group,while LVEF and 6min maximum walking distance were markedly higher than those of the control group（P 0.05）.The total efficiency of L-carnitine group and contorl group were respectively 96.7% and 80%,which was significantly higher in the L-carnitine group than that of the control group（P0.05）.No statistically significant difference of was observed in the occurrence of adverse reactions between two groups（P0.05）.Conclusion： Conventional treatment combined with L-carnitine ccould significantly improve the cardiac function,increase the exercise capacity and improve the prognosis of patients with chronic heart failure with no obvious adverse reactions,and is worthy of clinical application.
出处
《现代生物医学进展》
CAS
2013年第15期2914-2917,共4页
Progress in Modern Biomedicine
基金
国家自然科学基金项目(30570073)
